Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET

Company Participants

Paul Little – Chief Financial Officer

David-Alexandre Gros – Chief Executive Officer

Steve Perrin – President and Chief Scientific Officer

Jeff Bornstein – Chief Medical Officer

Conference Call Participants

Pete Stavropoulos – Cantor Fitzgerald

Matt Kaplan – Ladenburg Thalmann

Thomas Smith – SVB Securities

Rami Katkhuda – LifeSci Capital

Operator

Good day and welcome to the Eledon Pharmaceuticals Third Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. Please note, this event is being recorded.

I would now like to turn the conference over to Paul Little, Chief Financial Officer of Eledon. Mr. Little, please go ahead.

Paul Little

Good afternoon, everyone and thank you for joining Eledon’s third quarter 2022 operating and financial results conference call. Today, I’m joined by David-Alexandre Gros, Chief Executive Officer; Steve Perrin, our President and Chief Scientific Officer and Jeff Bornstein, our Chief Medical Officer. Earlier today, Eledon issued a press release announcing financial results for the third quarter ended September 30, 2022. You may access the release under the Investors tab on our company's website at eledon.com.

I would like to remind everyone that statements made during this conference call relating to Eledon’s expected future performance, future business prospects or future events or plans may include forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual outcomes and results could differ materially from those forecasts due to the impact of many factors beyond the control of Eledon. Eledon expressly disclaims any duty to provide updates to its forward-looking statements, whether as a result of new information, future events or otherwise. Participants are directed to the risk factors set forth in Eledon’s reports filed with the U.S. Securities and Exchange Commission.

Now I would like to pass the call to Eledon’s CEO, Dr. David-Alexandre Gros. DA?

David-Alexandre Gros

Thank you, Paul and thank you all for joining the call today. Following the positive Phase 2a ALS results in the second quarter, we continue to make important progress in our three ongoing clinical trials, evaluating tegoprubart in kidney transplantation, IgA Nephropathy or IgAN and islet cell transplantation.